Changes in fibrinolytic activity and coagulation factors after epicardial left atrial appendage closure in patients with atrial fibrillation.
Left atrial appendage (LAA)
atrial fibrillation (AF)
coagulation
left atrial appendage occlusion (LAAO)
thrombus
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
06
12
2021
accepted:
19
05
2022
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
17
12
2022
Statut:
ppublish
Résumé
The left atrial appendage (LAA) is known to be the primary source of thrombus formation in atrial fibrillation (AF). We investigate whether epicardial LAA occlusion (LAAO) from the cardiovascular system has an effect on coagulation and prothrombotic status in AF. Twenty-two patients with nonvalvular AF, who were not currently receiving oral anticoagulation (OAC) therapy, participated in a single-center prospective study. We measured fibrinogen and plasminogen levels along with plasma fibrin clot permeability, clot lysis time (CLT) and endogenous thrombin potential (ETP) before the LAAO procedure, at discharge and 1 month afterward. One month after the LAAO procedure, plasma fibrin clot permeability improved by 39.3% as measured by clots prepared from peripheral blood (P=0.019) and also after adjustment for fibrinogen (P=0.027). Higher plasma fibrin clot permeability was associated with improved clot susceptibility to lysis (r=-0.67, P=0.013). CLT was reduced by 10.3% (P=0.0020), plasminogen activator inhibitor-1 antigen levels were reduced by 52% (P=0.023) and plasminogen activity was increased by 8.9% (P=0.0077). A trend toward decreased thrombin generation, reflected by a decreased ETP and peak thrombin generated was also observed 1 month after LAAO procedure (P=0.072 and P=0.087, respectively). No differences were observed in tissue-type plasminogen activator and thrombin-activatable fibrinolysis inhibitor plasma levels (both P>0.05). Obtained results seem to confirm that LAA plays a key role in thrombogenesis. Elimination of LAA from the circulatory system may improve fibrin clot permeability and susceptibility to fibrinolysis in peripheral blood.
Sections du résumé
Background
UNASSIGNED
The left atrial appendage (LAA) is known to be the primary source of thrombus formation in atrial fibrillation (AF). We investigate whether epicardial LAA occlusion (LAAO) from the cardiovascular system has an effect on coagulation and prothrombotic status in AF.
Methods
UNASSIGNED
Twenty-two patients with nonvalvular AF, who were not currently receiving oral anticoagulation (OAC) therapy, participated in a single-center prospective study. We measured fibrinogen and plasminogen levels along with plasma fibrin clot permeability, clot lysis time (CLT) and endogenous thrombin potential (ETP) before the LAAO procedure, at discharge and 1 month afterward.
Results
UNASSIGNED
One month after the LAAO procedure, plasma fibrin clot permeability improved by 39.3% as measured by clots prepared from peripheral blood (P=0.019) and also after adjustment for fibrinogen (P=0.027). Higher plasma fibrin clot permeability was associated with improved clot susceptibility to lysis (r=-0.67, P=0.013). CLT was reduced by 10.3% (P=0.0020), plasminogen activator inhibitor-1 antigen levels were reduced by 52% (P=0.023) and plasminogen activity was increased by 8.9% (P=0.0077). A trend toward decreased thrombin generation, reflected by a decreased ETP and peak thrombin generated was also observed 1 month after LAAO procedure (P=0.072 and P=0.087, respectively). No differences were observed in tissue-type plasminogen activator and thrombin-activatable fibrinolysis inhibitor plasma levels (both P>0.05).
Conclusions
UNASSIGNED
Obtained results seem to confirm that LAA plays a key role in thrombogenesis. Elimination of LAA from the circulatory system may improve fibrin clot permeability and susceptibility to fibrinolysis in peripheral blood.
Identifiants
pubmed: 36524072
doi: 10.21037/jtd-21-1093
pii: jtd-14-11-4226
pmc: PMC9745526
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4226-4235Informations de copyright
2022 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-21-1093/coif). KB and his institutions Jagiellonian University Medical College and John Paul II Hospital in Krakow Poland were recipients of the research grant No. UMO-2015/17/B/NZ5/00125 and No. UMO-2019/33/B/NZ5/02395 funded by the Polish National Science Centre. The other authors have no conflicts of interest to declare.
Références
Pol Arch Med Wewn. 2011 Nov;121(11):400-7
pubmed: 22064373
N Engl J Med. 2021 Jun 3;384(22):2081-2091
pubmed: 33999547
PLoS One. 2018 Dec 19;13(12):e0208710
pubmed: 30566961
Ann Cardiothorac Surg. 2014 Jan;3(1):45-54
pubmed: 24516797
Ann Thorac Surg. 1996 Feb;61(2):755-9
pubmed: 8572814
Cerebrovasc Dis. 2019;47(3-4):188-195
pubmed: 31121584
Biomed Res Int. 2017;2017:3678017
pubmed: 28713823
Eur Rev Med Pharmacol Sci. 2000 May-Jun;4(3):59-66
pubmed: 11558626
J Clin Epidemiol. 1988;41(2):105-14
pubmed: 3335877
Int J Cardiol. 2020 Feb 15;301:103-107
pubmed: 31787387
JACC Cardiovasc Interv. 2014 Mar;7(3):296-304
pubmed: 24650403
Eur Heart J. 2012 Nov;33(21):2719-47
pubmed: 22922413
Postepy Kardiol Interwencyjnej. 2019;15(2):251-254
pubmed: 31497060
Catheter Cardiovasc Interv. 2019 Nov 15;94(6):837-842
pubmed: 30884101
JACC Cardiovasc Interv. 2015 Dec 28;8(15):1915-1921
pubmed: 26738659
Thromb Res. 2016 Apr;140:59-65
pubmed: 26901851
J Am Coll Cardiol. 2012 Aug 7;60(6):531-8
pubmed: 22858289
J Diabetes. 2019 Jan;11(1):75-82
pubmed: 29999242
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Vascul Pharmacol. 2020 Oct - Nov;133-134:106783
pubmed: 32835836
Am Heart J. 1998 Dec;136(6):956-60
pubmed: 9842006
Thromb Haemost. 1996 Feb;75(2):219-23
pubmed: 8815563
Pol Arch Intern Med. 2018 May 30;128(5):327-329
pubmed: 29768394
Thromb Res. 2015 Aug;136(2):408-14
pubmed: 26048399
Circulation. 2002 Oct 8;106(15):1938-42
pubmed: 12370216
Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1738-45
pubmed: 16728654
Thromb Haemost. 2014 Mar 3;111(3):385-91
pubmed: 24305974
Thromb Haemost. 2015 Apr;113(4):851-61
pubmed: 25518887
Circ Arrhythm Electrophysiol. 2014 Aug;7(4):764-7
pubmed: 25140024
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041
J Thromb Haemost. 2018 May;16(5):1007-1012
pubmed: 29658191
Kardiochir Torakochirurgia Pol. 2015 Dec;12(4):298-303
pubmed: 26855643